US/UK/Canada

Share

Pick a time period -
Tags ( Active)

APIM THERAPEUTICS ANNOUNCEs PUBLICATION OF PRECLINICAL RESEARCH OF ATX-101 IN GLIOBLASTOMA

APIM Therapeutics (APIM), a clinical stage biotech company, focusing on the development of novel peptide therapeutics targeting PCNA (Proliferating Cell Nuclear Antigen), announced today the publication of research data of ATX-101 in glioblastoma preclinical models in the peer reviewed journal Cancers. The article entitled “ATX-101, a Peptide Targeting PCNA, has antitumor efficacy alone or in combination with Radiotherapy in murine models of human glioblastoma” investigated ATX-101, the lead compound of APIM’s development program, in a panel of human glioblastoma (GBM) and patient-

APIM THERAPEUTICS ANNOUNCES INITIATION OF PATIENT RECRUITMENT IN A SARCOMA PHASE II STUDY

Trondheim/New York, December 10, 2021 APIM Therapeutics (APIM), a clinical stage biotech company focusing on the development of novel peptide therapeutics targeting PCNA (Proliferating Cell Nuclear Antigen), announced today that a Phase II Investigator Initiated Study (IIS) of ATX-101 will begin enrolling patients with sarcoma at Columbia University Irving Medical Center. The clinical study (ClinicalTrials.gov Identifier: NCT05116683) will investigate ATX-101, the lead compound of APIM’s development program, as single agent therapy for patients with leiomyosarcoma and liposarcoma who

APIM THERAPEUTICS ANNOUNCES THAT THE FIRST PATIENT HAS BEEN TREATED WITH ATX-101 IN A PHASE I/II OVARIAN CANCER STUDY

Trondheim, 25 November 2021 APIM Therapeutics (APIM), a clinical stage biotech company, focusing on the development of novel peptide therapeutics targeting PCNA (Proliferating Cell Nuclear Antigen), announced today that the first patient has been treated in a clinical Phase 1b/2a study in ovarian cancer. The clinical study (ClinicalTrials.gov Identifier: NCT04814875) investigates ATX-101, the lead compound of APIM’s development program, in combination with platinum-based chemotherapy in patients suffering from recurrent, platinum sensitive ovarian, fallopian tube and primary

APIM THERAPEUTICS COMPLETES PRIVATE PLACEMENT AND ENTERS PHASE-2 CLINICAL DEVELOPMENT

Trondheim, 18 May 2021 APIM Therapeutics AS (“APIM Therapeutics” or the “Company”), an oncology focused biotechnology company developing innovative anti-cancer treatments targeting stress responses in tumor cells, is pleased to announce the completion of a private placement directed towards existing and certain new investors in the Company (the “Private Placement”). “We are pleased to welcome 11 new investors to our existing strong shareholder base. The proceeds from this round put APIM Therapeutics in a strong position to advance the Company’s solid science to further clinical

There are no items matching the current filter
There are no more items matching the current filter
Back to top